Dissolvable CBD Tablets

View More

Renewsha's Orally Dissolvable Tablets Support Immune System Health

Renewsha makes taste-free dissolvable CBD tablets that support immuno-health by offering inflammation relief. While many people already rely on Renewsha as a daily supplement, an increasing number of people are looking for simple solutions to bolster their health and wellness—especially during a worldwide pandemic.

There are plenty of diluted oil-based CBD products that can be administered via a dropper but this ultra-portable solution is compact, mess-free and doesn't require liquid to be transported. Each Renewsha tablet has a precise 30-milligram dose of CBD that's tested with a third-party lab to certify its quality.

With these flavorless tablets, consumers can experience the benefits of CBD in a new way that's safe, enjoyable and fast-acting, without having to worry about guesswork or having an unpleasant taste experience.
Trend Themes
1. Dissolvable CBD Tablets - Opportunity for CBD companies to innovate with taste-free and fast-acting dissolvable tablets for easy consumption.
2. Immuno-health Supplements - Opportunity for supplement companies to develop products that support immune system health, especially during a worldwide pandemic.
3. Portable Wellness Solutions - Opportunity to create compact and mess-free wellness products that can be easily transported and consumed on the go.
Industry Implications
1. CBD Products - Disruptive innovation opportunities in the CBD industry through the development of taste-free, precise-dose, and third-party lab-tested dissolvable tablets.
2. Supplement Industry - Disruptive innovation opportunities for supplement companies by focusing on immune system support and developing convenient and effective products like dissolvable tablets.
3. Wellness Industry - Disruptive innovation opportunities in the wellness industry by creating portable and hassle-free products that enhance health and wellness, such as dissolvable tablets.

Related Ideas

Similar Ideas
VIEW FULL ARTICLE